The ART of Japanese Market Entry

Japan is one of the world’s most attractive pharmaceutical markets—but unlocking its potential requires more than regulatory approval. With unique pricing structures, mandatory in-country hires and rigorous commercialization requirements, market entry can be deceptively complex for global biopharma companies.

In this white paper, Syneos Health Consulting leaders outline the ART of Japanese market entry—Asset, Resource and Timeline. This is a proprietary framework designed to help companies plan with precision and execute with confidence. From navigating the cost-based reimbursement system to optimizing go-to-market models and mastering the market authorization holder (MAH) process, this guide breaks down what it takes to succeed in Japan’s highly regulated but innovation-friendly environment.

Download the full white paper to learn:

• How Japan’s pricing and premium structures impact asset valuation
• What leadership roles are legally required to gain marketing authorization
• When and how to outsource versus build in-house capabilities
• How to forecast revenue and prioritize strategic timelines for launch